Targeted Inhibition of FBXL2 Confers Susceptibility of HER2-Negative Breast Cancer to Trastuzumab Deruxtecan

Scientists discovered that targeted inhibition of F-box protein FBXL2 elevates HER2 expression on the plasma membrane of HER2-immunohistochemistry score 0 TNBC cells, thereby sensitizing them to trastuzumab deruxtecan.